Drug Type Small molecule drug |
Synonyms Gumarontinib, Gumarontinib Hydrate + [4] |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (07 Mar 2023), |
RegulationConditional marketing approval (CN), Special Review Project (CN), Orphan Drug (US), Breakthrough Therapy (CN), Priority Review (CN) |
Molecular FormulaC21H17N9O2S |
InChIKeyRYBLECYFLJXEJX-UHFFFAOYSA-N |
CAS Registry1642581-63-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
c-Met positive non-small cell lung cancer | JP | 24 Jun 2024 | |
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer | CN | 07 Mar 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
c-Met positive Adenocarcinoma of Esophagus | Phase 2 | CN | 31 Jul 2019 | |
Pulmonary sarcomatoid carcinoma | Phase 2 | CN | 31 Jul 2019 | |
Pulmonary sarcomatoid carcinoma | Phase 2 | CN | 31 Jul 2019 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | JP | 15 Jul 2019 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 15 Jul 2019 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | 15 Jul 2019 | |
c-Met positive non-small cell lung cancer | Phase 2 | CN | 15 Jul 2019 | |
c-Met positive non-small cell lung cancer | Phase 2 | US | 15 Jul 2019 | |
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer | Phase 2 | US | 15 Jul 2019 | |
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer | Phase 2 | JP | 15 Jul 2019 |
Phase 2 | 84 | SCC244 300 mg once daily | (zjcdampqmm) = tkjkhsbofx ugzkplviau (nwbsfpyreg, 54.3 - 76.1) View more | Positive | 07 Dec 2024 | ||
SCC244 300 mg once daily (treatment-naïve) | (zjcdampqmm) = mnjtditegk ugzkplviau (nwbsfpyreg, 54.8 - 83.2) View more | ||||||
Phase 1/2 | 32 | (fvlhtddyfo) = hwknywebse eyauvcprlp (ylzwasxeam, 63.6 - 92.8) View more | Positive | 01 Jan 2024 | |||
Phase 1/2 | 84 | wcjvxowoki(kofejgqkdt) = 32/84, 38% ipjzyotitm (ulxomcdklm ) View more | - | 01 May 2023 | |||
Phase 1 | 32 | (shgqpeshot) = osoupjawyw asvpazhdpa (ulvaysavij, 21.1 - 56.3) View more | Positive | 03 Dec 2022 | |||
(treatment naïve patients) | (shgqpeshot) = ualilgyvvy asvpazhdpa (ulvaysavij, 15.2 - 72.3) | ||||||
Phase 2 | 30 | (rklgppfdkd) = evwsxuopjf ypfignnoht (vqkbpaatgy, [40.6 - 77.3]) View more | - | 03 Dec 2022 | |||
Phase 1 | Non-Small Cell Lung Cancer c-MET status | c-MET ex14 skipping mutation | c-MET IHC 3+ | 19 | (khbnvwbioq) = sjdynpbdxp afoxovgoss (waaodgqcpl ) View more | - | 01 Mar 2021 | ||
Phase 1 | 18 | lhrnwwolgv(wqxsqdaonj) = Peripheral edema (n = 1, 5.5%), hypothyroidism (n = 1, 5.5%) dommtraosy (eafgfqxxvm ) View more | Positive | 25 May 2020 |